{"entity":{"id":"nct06549946","kind":"trial","name":"Ixovex-1 Single Agent and Combination Therapy","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab in head and neck squamous cell carcinoma, run by Psivac Ltd, now recruiting.","summary":"Ixovex-1 Single Agent and Combination Therapy is a phase 1/2 interventional study registered as NCT06549946 by Psivac Ltd, with 18 participants planned, started 2024-12-17 and due to reach its primary completion in 2027-01-30. Interventions recorded: Ixovex-1 and Pembrolizumab.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06549946","url":"https://clinicaltrials.gov/study/NCT06549946"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab"],"companies":["iqvia"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06549946","phase":"1/2","setting":"A Phase I/II Open-label, Clinical Trial of Intratumoural Ixovex-1 as Single Agent Therapy or in Combination With Pembrolizumab in Palpable Solid Tumours","sponsor":"Psivac Ltd","enrolled":18,"outcomes":[]},"route":"/trials/nct06549946/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"iqvia","kind":"company","name":"IQVIA","route":"/companies/iqvia/"}]}}